A Study to Investigate the Safety and Biodistribution of a Single Intrathecal (IT) Injection of INS1201 in Ambulatory Males With Duchenne Muscular Dystrophy (DMD)

Launched by INSMED GENE THERAPY LLC · Feb 4, 2025

Keywords

ClinConnect Summary

This clinical trial is investigating the safety and effects of a single injection of a treatment called INS1201 for boys with Duchenne Muscular Dystrophy (DMD). DMD is a genetic condition that causes muscle weakness and affects movement. The main goal of this study is to see if INS1201 is safe to use and how it spreads in the body after being injected into the spinal area. The trial is currently looking for boys aged 2 to 5 years who can walk at least 10 meters on their own and have been diagnosed with DMD based on specific genetic tests.

Participants in this study will receive one injection and will be monitored for any side effects or changes in their condition. To be eligible, participants must be boys who were assigned male at birth, meet the age requirements, and be able to walk without assistance. However, there are some exclusions, such as if they have had certain previous treatments or serious health conditions. This trial offers a chance to explore a new treatment for DMD, and families can expect close support and monitoring throughout the process.

Gender

MALE

Eligibility criteria

• • Inclusion Criteria
• • Participant must be male at birth, 3 to \<5 years of age, inclusive (Part 1) and 2 to \<3 years of age (Part 2), at the time of legally authorized representative (LAR) signing and dating the informed consent form.
• • Ambulatory -as defined as the ability to walk at least 10 meters unassisted (i.e., without personal assistance or use of any assistive devices) Note: children who have not yet developed the ability to walk by the time of screening (for whatever reason) will not be eligible for the study.
• • Has a definitive diagnosis of DMD prior to Screening based on genetic testing. Genetic report must describe a frameshift deletion, frameshift duplication, premature stop ("nonsense"), canonical splice site mutation, or other pathogenic variant in the DMD gene fully contained between exons 18 to 58 (inclusive) that is expected to lead to absence of a functional dystrophin protein.
• • Able to cooperate with motor assessment testing.
• • Has received vaccinations recommended for the participant's age and DMD disease according to Centers for Disease Control and Prevention (CDC) recommendation on Child and Adolescent Immunization Schedule by Age, incorporating the Advisory Committee on Immunization Practices (ACIP) Vaccine Recommendations and Guidelines for Patients with Altered Immunocompetence.
• • Exclusion Criteria
• • Prior treatment with gene or cell-based therapy at any time.
• • Oligonucleotide-based exon skipping or small molecule stop codon readthrough-promoting therapies for at least 6 months prior to enrolment.
• • Mutations in DMD gene between or including exons 1-17 and/or 59-71.
• • Total adeno-associated virus (AAV) binding antibody titers \> 1:50 as determined by Enzyme-linked immunosorbent assay (ELISA) within 7 days prior to Day 1.
• • Has left ventricular ejection fraction \< 50% on the screening echocardiogram (ECHO) or clinical signs and/or symptoms of cardiomyopathy.
• • Has cardiac arrhythmia or significant electrocardiogram (ECG) interval abnormalities.
• • Major surgery within 3 months prior to Day 1 or planned surgery or procedures that would interfere with the conduct of the study at any time during this study.
• * The presence of any other clinically significant illness, including cardiac, pulmonary, hepatic, renal, hematologic, immunologic/allergic, behavioural disease, infection, unhealed injury, malignancy, concomitant illness, extenuating circumstance, or requirement for chronic drug treatment that, in the opinion of the Investigator:
• • 1. Creates unnecessary risks for undergoing gene transfer;
• • 2. Might compromise the participant's ability to comply with the protocol-required testing or procedures; or
• • 3. Might compromise the participant's wellbeing, safety, or clinical interpretability.
• • Has serological evidence of current, chronic, or active human immunodeficiency virus, hepatitis C, or hepatitis B infection.
• • Has signs of clinically significant symptomatic infection (e.g., upper respiratory tract infection, pneumonia, pyelonephritis, meningitis) within 4 weeks prior to Day 1.
• • Has contraindications for IT administration of the product or for lumbar puncture, such as anatomical abnormalities, bleeding disorders or other medical conditions (e.g., spina bifida, meningitis, or significant clotting abnormalities).
• • Demonstrates cognitive or developmental delay or impairment that could confound assessment of motor development in the opinion of the Investigator.
• • Note: Other inclusion/exclusion criteria may apply.